Page 83 - SDIR5 Abstract book 21 12 2021.

POSTER PRESENTATIONS

P43

Selected polyoxopalladates as potential antitumor drug candidates

1
1
2
3
4
Marija Jeremic , Andjelka M. Isakovic , Danijela Krstić , Mirjana B. Čolović , Ulrich Kortz , Sonja Misirlic-
Dencic 1
1 Institute of Medical and Clinical Biochemistry, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
2 Institute of Medical Chemistry, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
3 Department of Physical Chemistry, “Vinča” Institute of Nuclear Sciences-National Institute of the Republic of
Serbia, University of Belgrade, Belgrade, Serbia
4 Department of Life Sciences and Chemistry, Jacobs University, Bremen, Germany

Background: Polyoxo-noble-metalates, a class of molecular noble metal-oxo nanoclusters that combine
features of both polyoxometalates and noble metals, are a promising platform for the development of next-
generation antitumor metallodrugs. The aim of this study was to evaluate the antineuroblastoma potential
of three novel polyoxopalladates. Material and methods: All experiments were performed on human
neuroblastoma cell line, SHSY5Y. The three polyoxo-noble-palladates Na4[SrPd12O6(OH)3(PhAsO3)6(OAc)3]
IV
IV
・2NaOAc・32H2O (SrPd12), Na12[Sn O8Pd12(PO4)8]·43H2O (SnPd12) and Na12[Pb O8Pd12(PO4)8]·38H2O
(PbPd12) were investigated in our study. The viability of neuroblastoma cells after 24h treatment was
assessed using an acid phosphatase assay. The level of superoxide ion, mitochondrial membrane potential,
pan-caspase activity, cell cycle analysis and acidic vesicles content were determined by flow cytometry
using appropriate fluorochromes. Results: Calculated IC50 (μM; 24h) values were 75.8 ± 6.7 (SrPd12) and
>>100 (SnPd12 and PbPd12), selecting SrPd12 as the most efficient. SrPd12 did not affect the mitochondrial
membrane potential and superoxide production in neuroblastoma cells after short (2 h and 4 h) exposure.
Also, it did not induce an increase in the number of neuroblastoma cells with fragmented DNA content, but
displayed the cell cycle arrest: the ~ 23% reduction of neuroblastoma cells in G0/G1 phase and the ~ 17%
increase in S phase. The treatment with SrPd12 did not increase the level of acidic vesicles but it increased
the activity of caspases five-fold. Conclusion: Only SrPd12 exhibited a satisfactory antineuroblastoma action
by inducing caspase activation and neuroblastoma cell cycle arrest.
Keywords: polyoxopalladates, neuroblastoma, antitumor

70